SavedAdd your journal

Journals / Ankara Sağlık Bilimleri Dergisi / 2019 / Cilt: 8 - Sayı: 1

X-LINKED ADRENOLEUKODYSTROPHY (ALD) DISEASE AND USAGE OF LORENZO'S OIL IN THE TREATMENT PROCESS

X’E BAĞLI ADRENOLÖKODİSTROFİ (ALD) HASTALIĞI VE TEDAVİ SÜRECİNDE LORENZO’NUN YAĞI KULLANIMI

Ayşe Hümeyra İSLAMOĞLU
Pages
154–159
Publication Date
2019-06-25
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Therefore, early diagnosis is crucial.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:X-linked adrenoleukodystrophy disease (ALD) is known as a peroxisomal disease which causes accumulation of very long-chain fatty acids (VLCFA) in the blood due to the deficiency in the beta oxidation of fats.
📊
Key Findings & Data:While the incidence in the whole population is 1.3/100.000, the incidence in men is reported to be 1/20.000.
💡
Conclusion & Impact:Therefore, early diagnosis is crucial.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:X-linked adrenolökodistrofi · ALD · Lorenzo’nun Yağı

Abstract

X-linked adrenoleukodystrophy disease (ALD) is known as a peroxisomal disease which causes accumulation of very long-chain fatty acids (VLCFA) in the blood due to the deficiency in the beta oxidation of fats. This accumulation affects the central nervous system and adrenal cortex and causes deterioration in motor and mental functions. The clinical spectrum ranges from rapid progressive demyelination or slowly progressing myelopathy to adrenal insufficiency. The most common forms; childhood cerebral form, Addison and Adrenomyeloneuropathy (AMN). While the incidence in the whole population is 1.3/100.000, the incidence in men is reported to be 1/20.000. In patients with asymptomatic ALD, improvement can be seen with the addition of Lorenzo's Oil, which contains the triglyceride forms (edible form) of oleic and erucic acid. Therefore, early diagnosis is crucial.

Özet

X’e bağlı adrenolökodistrofi hastalığı (ALD), yağların beta oksidasyonundaki bozukluk sebebiyle çok uzun zincirli yağ asitlerinin (ÇUZYA) kanda birikimine sebep olan peroksizomal bir hastalık olarak bilinmektedir. Bu birikim santral sinir sistemini ve adrenal korteksi etkileyerek motor ve mental işlevlerde bozukluğa yol açmaktadır. Klinik spektrumda hızlı ilerleyen demiyelinizasyon veya yavaş ilerleyen miyelopatiden adrenal yetersizliğe kadar uzanmaktadır. En sık görülen formları; çocukluk dönemi serebral form, Addison ve Adrenomiyelonöropati (AMN)’dir. Tüm popülasyonda görülme sıklığı 1.3/100.000 olmakla birlikte, erkeklerde görülme sıklığı 1/20.000 olarak bildirilmektedir. Asemptomatik ALD hastalarında diyete oleik ve erusik asidin trigeliserit formlarını (yenilebilir form) içeren Lorenzo’nun Yağı’nın eklenmesi ile düzelme görülebilmektedir. Bu sebeple erken tanı ve teşhis büyük önem taşımaktadır.

🔖

Cite This Article

İSLAMOĞLU, A. H. (2019). X-LINKED ADRENOLEUKODYSTROPHY (ALD) DISEASE AND USAGE OF LORENZO'S OIL IN THE TREATMENT PROCESS. Ankara Sağlık Bilimleri Dergisi, Cilt: 8 - Sayı: 1, 154–159. https://ajindex.com/articles/734305

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Berger J., Forss-Petter S., Eichler F.S. 2014. Pathophysiology of X-linked adrenoleukodystrophy, Biochimie; 98:135–142.
  2. Berger J., Gärtner J. 2006. X-linked adrenoleukodystrophy: Clinical, biochemical and pathogenetic aspects, Biochimica et Biophysica Acta; 1763:1721–1732.
  3. Craemer D.D., Van den Branden C., Fontaine M., et al. 1998. Effects of Lorenzo’s Oil on Peroxisomes in Healthy Mice, Prostaglandins Other Lipid Mediat.; 55:237-244.
  4. Eichler F., Auborg P. 2008. Therapeutics of X-linked adrenoleukodystrophy, Drug Discov Today Ther Strateg.; 5(4). Kemp S., Berger J., Aubourg P. 2012. X-linked adrenoleukodystrophy: Clinical, metabolic, genetic and pathophysiological aspects, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease; 1822(9):1465–1474.
  5. Maier E.M., Kammerer S., Muntau A.C., et al. 2002. Symptoms in carriers of adrenoleukodystrophy relate to skewed X inactivation, Ann. Neurol.; 52:683–688.
  6. Miller W.P., Rothman S.M., Nascene D., et al. 2011. Outcomes following allogenic hematopoetic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood;118:1971-8.
  7. Moser H.W., Mahmood A., Raymond G.V. 2007.
  8. X-linked adrenoleukodystrophy, Nat. Clin. Pract. Neurol.; 3(3):140–151.
  9. Moser H.W., Raymond G.V., Lu S.E., et al. 2005. Follow-up of 89 Asymptomatic Patients With Adrenoleukodystrophy Treated With Lorenzo’s Oil, Arch Neurol.; 62(7):1073-1080.
  10. Moser H.W., Raymond G.V., Koehler W., et al. 2003. Evaluation of the Preventive Effect of Glyceryl Trioleate-Trierucate (“Lorenzo’s Oil”) Therapy in X-Linked Adrenoleukodystrophy: Results of Two Concurrent Trials, Peroxisomal Disorders and Regulation of Genes; 544:369-387.
  11. Moser H.W., Smith K.D., Watkins P.A., et al. 2001. X-linked adrenoleukodystrophy, in: C.R. Scriver, A.L. Beaudet (Eds.), The metabolic and molecular bases of inherited disease; 8:3257–3301. Moser H.W. 1993. Lorenzo oil therapy for adrenoleukodystrophy: a prematurely amplified hope, Ann Neurol; 34(2):121-2. Olcay N., 2010. Peroksizmal Hastalıklar. Pediyatri; 885. Öner, A.F., Özer, R., Anlar, Ö., vd. 1999. Adrenolökodistrofi (Addison – Schilder Hastalığı): İki Erkek Kardeş Sunumu, Van Tıp Dergisi; 6(2). Raymond, G.V. 2015. Rosenberg’s Molecular and Genetik Basis of Neurological and Psychiatric Disease; 5:713-24.
  12. Senior, K. 2002. Lorenzo's oil may help to prevent ALD symptoms. Lancet Neurol;1(8), 468. Shimozawa N. 2007. Molecular and clinical aspects of peroxisomal diseases. J Inherit M